Vertex (VERX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Vertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditio…

Maze Therapeutics, Inc. is positioned as the only APOL1 inhibitor competitor to Vertex, with strong Phase 2 data and funding into 2029. MAZE's HORIZON trial showed robust uACR reductions, especially in non-diabetic and s…

BioNTech is aggressively pivoting its mRNA technology toward a deep pipeline of oncology treatments. Vertex Pharmaceuticals maintains high profitability and a dominant market share in cystic fibrosis therapies.…

KING OF PRUSSIA, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released the 2026 Vertex CompOps™…

Vertex (VERX) could produce exceptional returns because of its solid growth attributes.…

Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant positio…

Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.…

Vertex Inc (NASDAQ:VERX) on Wednesday reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.…

Vertex NASDAQ: VERX raised its full-year revenue and earnings guidance after reporting third-quarter revenue growth of 11% and a nearly 50% increase in adjusted earnings before interest, taxes, depreciation and amortizat…

Vertex, Inc. (VERX) Q3 2026 Earnings Call Transcript…

While the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street est…

Vertex (VERX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago.…

KING OF PRUSSIA, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced financial results for …

VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.…

VRTX beats Q3 revenue estimates and raises its 2026 outlook as CF therapies and newer drugs drive growth, but acquisition costs pressure earnings.…

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.…

Vertex Pharmaceuticals NASDAQ: VRTX reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURN…

Alyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise. Heavy spending on new launches and the Crinetics deal kept profit from rising with sales.…

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. “V…

AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management software and payroll tax management solutions, and Vertex, Inc. (NASDAQ:VER…

VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.…

Starting with the tax decision, Vertex Sōl connects the work, evidence, and AI that tax professionals control Starting with the tax decision, Vertex Sōl connects the work, evidence, and AI that tax professionals control…

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I'll be watching whether CASGEVY and JOURNAVX stay on pace for management's …

The biotech company has grown its annual revenue by more than 600% over the past decade. Kidney disease therapy inaxaplin is seen as a possible blockbuster drug.…

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years …

APPLETON, Wis.--(BUSINESS WIRE)--IGEN, an industry leader in excise tax compliance automation, today announced an expansion of its strategic collaboration with Vertex, Inc., the Decision-to-Defense™ global indirect tax a…

Recognition highlights Vlasic's leadership of Vertex's enterprise AI and data transformation and her commitment to developing the next generation of women in technology Recognition highlights Vlasic's leadership of Verte…

KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that it will release third quarter 2026 financial …
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

